Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 12(2): e0172627, 2017.
Article in English | MEDLINE | ID: mdl-28235018

ABSTRACT

Burkholderia pseudomallei, the etiologic agent of melioidosis, is a Gram negative bacterium designated as a Tier 1 threat. This bacterium is known to be endemic in Southeast Asia and Northern Australia and can infect humans and animals by several routes. Inhalational melioidosis has been associated with monsoonal rains in endemic areas and is also a significant concern in the biodefense community. There are currently no effective vaccines for B. pseudomallei and antibiotic treatment can be hampered by non-specific symptomology and also the high rate of naturally occurring antibiotic resistant strains. Well-characterized animal models will be essential when selecting novel medical countermeasures for evaluation prior to human clinical trials. Here, we further characterize differences between the responses of BALB/c and C57BL/6 mice when challenged with low doses of a low-passage and well-defined stock of B. pseudomallei K96243 via either intraperitoneal or aerosol routes of exposure. Before challenge, mice were implanted with a transponder to collect body temperature readings, and daily body weights were also recorded. Mice were euthanized on select days for pathological analyses and determination of the bacterial burden in selected tissues (blood, lungs, liver, and spleen). Additionally, spleen homogenate and sera samples were analyzed to better characterize the host immune response after infection with aerosolized bacteria. These clinical, pathological, and immunological data highlighted and confirmed important similarities and differences between these murine models and exposure routes.


Subject(s)
Burkholderia pseudomallei/immunology , Immunity, Innate , Liver/immunology , Lung/immunology , Melioidosis/immunology , Spleen/immunology , Administration, Inhalation , Animals , Bacterial Load , Body Temperature , Body Weight , Burkholderia pseudomallei/growth & development , Burkholderia pseudomallei/pathogenicity , Colony Count, Microbial , Cytokines/biosynthesis , Cytokines/immunology , Disease Models, Animal , Female , Granulocytes/immunology , Granulocytes/microbiology , Humans , Injections, Intraperitoneal , Liver/microbiology , Lung/microbiology , Lymphocyte Subsets/classification , Lymphocyte Subsets/immunology , Lymphocyte Subsets/microbiology , Melioidosis/microbiology , Melioidosis/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Monocytes/immunology , Monocytes/microbiology , Species Specificity , Spleen/microbiology
2.
PLoS One ; 11(3): e0148713, 2016.
Article in English | MEDLINE | ID: mdl-27007118

ABSTRACT

Several different human vaccines are available to protect against anthrax. We compared the human adaptive immune responses generated by three different anthrax vaccines or by previous exposure to cutaneous anthrax. Adaptive immunity was measured by ELISPOT to count cells that produce interferon (IFN)-γ in response to restimulation ex vivo with the anthrax toxin components PA, LF and EF and by measuring circulating IgG specific to these antigens. Neutralising activity of antisera against anthrax toxin was also assayed. We found that the different exposures to anthrax antigens promoted varying immune responses. Cutaneous anthrax promoted strong IFN-γ responses to all three antigens and antibody responses to PA and LF. The American AVA and Russian LAAV vaccines induced antibody responses to PA only. The British AVP vaccine produced IFN-γ responses to EF and antibody responses to all three antigens. Anti-PA (in AVA and LAAV vaccinees) or anti-LF (in AVP vaccinees) antibody titres correlated with toxin neutralisation activities. Our study is the first to compare all three vaccines in humans and show the diversity of responses against anthrax antigens.


Subject(s)
Adaptive Immunity/immunology , Anthrax Vaccines/immunology , Anthrax/immunology , Skin Diseases, Bacterial/immunology , Adult , Antibodies, Bacterial/immunology , Antigens, Bacterial/immunology , Bacterial Toxins/immunology , Female , Humans , Immune Sera/immunology , Immunoglobulin G/immunology , Interferon-gamma/immunology , Male , Middle Aged , Vaccination/methods
3.
FEMS Immunol Med Microbiol ; 62(1): 11-22, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21231965

ABSTRACT

Protective antigen (PA) from Bacillus anthracis binds to cellular receptors, combines with lethal factor (LF) forming lethal toxin (LeTx), and facilitates the translocation of LF into the cytosol. LeTx is cytotoxic for J774A.1 cells, a murine macrophage cell line, and causes death of Fisher 344 rats when injected intravenously. PA is also the major protective component in anthrax vaccines. Antibody-dependent enhancement has been reported for several viral diseases, a bacterial infection, and for B. anthracis LeTx in vitro cytotoxicity. Further screening of our 73 PA monoclonal antibodies (mAbs) identified a total of 17 PA mAbs that enhanced in vitro cytotoxicity at suboptimal concentrations of LeTx. A competitive binding enzyme-linked immunosorbent assay showed that these 17 PA mAbs identified eight different antigenic regions on PA. Eight of the 17 PA mAbs that enhanced LeTx in vitro cytoxicity were examined for their activity in vivo. Of the eight mAbs that were injected intravenously with a sublethal concentration of LeTx into male Fisher 344 rats, four mAbs enhanced the lethality of LeTx and resulted in the death of animals, whereas control animals did not succumb to intoxication. This is the first demonstration that PA mAbs can enhance LeTx intoxication in vivo.


Subject(s)
Anthrax/mortality , Antibodies, Monoclonal/immunology , Antibody-Dependent Enhancement , Antigens, Bacterial/immunology , Antigens, Bacterial/toxicity , Bacillus anthracis/pathogenicity , Bacterial Toxins/immunology , Bacterial Toxins/toxicity , Animals , Anthrax/immunology , Antibodies, Bacterial/immunology , Antibodies, Bacterial/metabolism , Antibodies, Monoclonal/metabolism , Bacillus anthracis/immunology , Cell Line , Macrophages , Male , Mice , Rats , Rats, Inbred F344
4.
J Infect Dis ; 199(3): 336-41, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19099484

ABSTRACT

BACKGROUND: Postexposure prophylaxis of inhalational anthrax requires prolonged antibiotic therapy or antibiotics and vaccination. The duration of treatment for established anthrax is controversial, because retained spores may germinate and cause disease after antibiotics are discontinued. Using rhesus macaques, we determined whether a short course of antibiotic treatment, as opposed to prophylaxis, could effectively treat inhalational anthrax and prevent disease caused by the germination of spores after discontinuation of antibiotics. METHODS: Two groups of 10 rhesus macaques were exposed to an aerosol dose of Bacillus anthracis spores. Animals in group 1 received ciprofloxacin prophylaxis beginning 1-2 h after exposure. Those in group 2 began receiving ciprofloxacin after becoming bacteremic, and treatment was continued for 10 days. When each group 2 animal completed 10 days of therapy, the prophylactic antibiotic was discontinued in the paired group 1 animal. RESULTS: In group 1 (prophylaxis), no deaths occurred during antibiotic treatment, but only 2 (20%) of 10 animals survived after antibiotics were discontinued. In contrast, in group 2 (treatment), 3 deaths occurred during antibiotic treatment, but all 7 animals (100%) alive after 10 days of therapy survived when antibiotics were discontinued. CONCLUSIONS: In the treatment of inhalational anthrax, the prolonged course of antibiotics required to achieve prophylaxis may not be necessary to prevent anthrax that results from the germination of retained spores after the discontinuation of antibiotics.


Subject(s)
Anthrax/drug therapy , Anthrax/mortality , Anti-Bacterial Agents/administration & dosage , Ciprofloxacin/administration & dosage , Administration, Inhalation , Aerosols , Animals , Anti-Bacterial Agents/therapeutic use , Bioterrorism , Ciprofloxacin/therapeutic use , Disease Models, Animal , Female , Macaca mulatta , Male , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...